Abstract: A compound of formula (I) R—S—CH2—CO—CF3 (I) wherein R is a C10-24 unsaturated hydrocarbon group comprising at least 4 non-conjugated double bonds; or a salt thereof; for use in the treatment of squamous cell carcinoma or actinic keratosis.

Abstract: The present invention relates to application of gossypol and its optical isomers to preparation of an anti-Coronavirus drug. Specifically disclosed is application of pharmaceutically acceptable salts, solvates, isotopes, stereoisomers, stereoisomer mixtures, and tautomers of the gossypol and its optical isomers to preparation of a drug for preventing and/or treating a disease caused by a Coronavirus. The Coronavirus is MERS-CoV, SARS-CoV, or SARS-CoV-2. It is found in the present invention for the first time that the gossypol and its optical isomers can inhibit the activity of Coronavirus 3CL proteases to achieve an anti-Coronavirus effect. The half maximal inhibitory concentrations of gossypol and (?)-gossypol to SARS-CoV proteases and SARS-CoV-2 3CL proteases are all lower than 10 ?M. The anti-Coronavirus 3CL protease effect is good. Therefore, the gossypol and its optical isomers have the potential for use in the preparation of a drug for preventing and/or treating novel Coronavirus infections.

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

Abstract: The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.

Abstract: The present invention is directed to a medicinal composition, and more particularly, to a composition of chlorhexidine to treat lesions, particularly lesions caused by cold sores and herpes. The composition comprises chlorhexidine as the active ingredient. The composition also comprises a component for pain relief and a component for anti-inflammation. These three components, which act efficaciously in concert, are then combined with a suitable emollient or vehicle to form a topical formulation effective to treat the symptoms of cold sores and herpes. The composition may be formulated as an over-the-counter (OTC) topical formulation.

Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.

Abstract: A method of treating an inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of a glucocorticoid receptor modulator comprising a therapeutically acceptable salt, solvate, or stereoisomer thereof of Adapalene as well as pharmaceutical compositions comprising Adapalene for the management of these inflammatory diseases.

Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

Abstract: The present disclosure relates to methods of treatment and compositions for treatment of Pathological Fatigue caused by injury or disease in the body. Pathological fatigue refers to physical and mental fatigue that is caused by viral infection, bacterial infection, trauma, disease, or genetic alteration that results in fatigue that is not improved by bed rest and may be worsened by physical or mental activity. Such pathologic fatigue occurs in myalgic encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) and other disorders such as such as post-COVID-19 fatigue, post-viral fatigue, fibromyalgia (FM), cancer, Parkinson's Disease, other diseases and trauma as well as of combinations thereof. Related treatment methods and pharmaceutical compositions are also disclosed.

Abstract: Methods and applications of the present disclosure include promoting blood clotting, controlling hemorrhage, and or inhibiting fibrinolysis in soldiers and civilians having experienced massive bleeding from a wound by administering antifibrinolytic agents, such as tranexamic acid, and or one or more procoagulants, in preferably autoinjector format.

Abstract: A creatine composition comprising a base component, a dianion component, and a creatine component. In some exemplary embodiment, the base component and dianion component can at least be partially reacted before being added to the creating component. On a dry weight basis, the base component can comprise between about 7-20% of the composition by weight, the dianion component can comprise between about 35-50% of the composition by weight, and the creatine component can comprise between about 30-60% of the composition by weight. In embodiments where the base component and dianion component are first reacted to form a base dianion component, the base dianion component can comprise between about 40-65% of the composition by weight. The creatine component can comprise between about 35-60% of the composition by weight with the remainder of the composition being composed of deionized water (i.e., between about 0-10% of the composition by weight).

Abstract: The current invention relates to pelargonic acid (C9) or derivatives thereof for use in the treatment or prevention of viral infections in animals and the use of pelargonic acid for mitigating the presence of viral particles in a feed, feed ingredients or drinking water of said animals.

Abstract: This disclosure relates to methods of use related to omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFA) and their hydroxylated derivatives known as elovanoids to alleviate a symptom of, treat, or prevent disease. Furthermore, this invention is directed to compositions and methods for modulating VLC-PUFA bioactivity and availability.

Abstract: The present invention relates to oxybutynin for use in the treatment of a medical condition, wherein oxybutynin is administered to the subject in need of treatment by means of a vaginal ring, that comprises a drug reservoir for the liquid formulation of oxybutynin and a pump for dispensing the oxybutynin. The medical condition comprises overactive bladder (OAB) or post-menopausal or aromatase inhibitor-induced hot flashes. The ring may further comprise a miniature electronic circuit board that controls the ring, and optionally a battery. The vaginal ring may be wirelessly connected to an external device for programming drug delivery or for transmitting and/or receiving data from the ring.

Abstract: Described herein are methods fir treating patients with iron-deficiency anemia (IDA), comprising administering ferric citrate to such patients. In certain aspects, the patients treated for iron-deficiency anemia have a gastrointestinal disorder, such as inflammatory bowel disease, inflammatory bowel syndrome, Crohn's disease, microscopic colitis (such as collagenous or lymphocytic colitis), or chemically-induced colitis (e.g., NSAID (nonsteroidal anti-inflammatory drug)-induced colitis). In certain aspects, the patients treated for iron-deficiency anemia have blood loss associated with childbirth, menstruation or infection. In some aspects, the patients treated for iron-deficiency anemia have insufficient dietary intake of iron and/or insufficient absorption of iron.

Abstract: The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.

Abstract: The disclosure relates to the technical field of extraction of an active ingredient from traditional Chinese medicine, and provides a method of extracting myricetin from Xanthoceras sorbifolia Bunge.

Abstract: The invention relates to a method of preventing or reducing suicidal ideation and/or desire for hastened death in a patient suffering from a life-threatening disease, the method comprising administering a psychedelic compound which is psilocin or a prodrug of psilocin, or a pharmaceutically acceptable salt thereof, to said patient. Kits useful in the method of the invention are also described.

Abstract: Embodiments of the present disclosure pertain to methods of treating or preventing a condition in a subject by administering to the subject a composition having alpha-methyl-L-tryptophan. In additional embodiments, the method further includes a step of instructing the subject to administer the composition in order to treat or prevent the condition in the subject. In some embodiments, the condition includes, without limitation, hyperglycemia, diet-induced diabetes, high-fat diet-induced diabetes, insulin resistance, metabolic syndrome, extra weight, obesity, hepatic steatosis, and combinations thereof. Additional embodiments of the present disclosure pertain to compositions for use in treating or preventing a condition in a subject. In some embodiments, the composition includes alpha-methyl-L-tryptophan.

Abstract: A method for treating amyotrophic lateral sclerosis includes administering an effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof to a patient who is in need thereof and meets two or more features selected from a group of identified features.

Abstract: The present disclosure provides compositions and methods for inhibiting respiratory viral infections, inflammatory diseases, and/or respiratory inflammation.

Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.

Abstract: Described herein are compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 ?M, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX/LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.

Abstract: An apparatus and method of manufacturing a sighting device mountable to a gun to assist a shooter in aiming at a target. The apparatus comprises an optical element and a light source which provide feedback to the user regarding alignment with a target. The alignment aid optical element is a ring of transparent material with a user-facing, contoured surface-coated with a reflective material that reflects a narrow band of light wavelengths—with an inner and outer edge. The apparatus further comprises a light source coupled to a mount located at a focal point of the lens wherein the emission of light from the light source faces the lens. The wavelengths emitted from the light source correspond to those of the coatings on the lens.

Abstract: The invention refers to an inhibitor of at least one S-adenosylmethionine (SAM) cycle enzyme for use in preventing or treating coronavirus disease 2019 (COVID-19) in a subject, or for use in preventing or treating of infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a subject, wherein the at least one SAM cycle enzyme is selected from the group consisting of methionine adenosyltransferase, betaine-homocysteine methyltransferase, methionine synthase, methionine synthase reductase and S-adenosylhomocys.

Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

Abstract: Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.

Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, b opioid maintenance and related methods are provided.

Abstract: Methods of treating mitochondrial fatty acid ?-oxidation and/or transport disorders arising from mutant proteins in the mitochondrial fatty acid ?-oxidation and transport metabolic pathways in patients are provided. The methods modulate the mitochondrial fatty acid ?-oxidation pathway at the last step so that the product of the mutant protein accumulates and stabilizes the mutant protein and/or the substrate(s)/product(s) of the downstream reactions accumulate and possibly bind to allosteric sites on the mutant protein to stabilize it. Trimetazidine pharmacodynamics function as such in the ?-oxidation pathway. Further, a synergistic effect is observed where a trimetazidine and PPAR? agonist combination enhanced enzyme activity and presence significantly more than either alone.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention relates to compositions comprising clofazimine and methods for treating cancer. In various embodiments, the compositions and methods further comprise a proteasome inhibitor and/or immunomodulatory drug. The compositions and methods of the present invention may be used for naïve cancers as well as those that have developed resistance to proteasome inhibitors and/or immunomodulatory drugs.

Abstract: Provided is a pharmaceutical composition comprising as active ingredients: 5 mg of tadalafil or a pharmaceutically acceptable salt thereof; and 0.5 mg of dutasteride or a pharmaceutically acceptable salt thereof, wherein the dissolution rate of tadalafil under the dissolution conditions of a paddle rate of 50 rpm in 500 mL of a dissolution solution having a pH of 1.2 and containing 0.25% of SLS is 60-75% after 5 minutes and 80% or more after 30 minutes, and the dissolution rate of dutasteride under the dissolution conditions of a paddle rate of 50 rpm in 500 mL of a dissolution solution containing water and 0.1% of SLS is 50% or more after 15 minutes and 85% or more after 30 minutes.

Abstract: The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.

Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST).

Abstract: The present disclosure provides methods of treating a subject with hereditary hemorrhagic telangiectasia using pazopanib, wherein the method includes identifying a hemorrhagic locus, determining a therapeutically effective amount of pazopanib as a function of the hemorrhagic locus, and administering the therapeutically effective amount of pazopanib to a subject for a period of at least 6 months. In addition, treatment is targeted to vascular densities throughout the body which drive hemodynamic compromise or cosmetic disfigurement. The present disclosure provides a method of ensconcing a powder form of a therapeutically effective amount of pazopanib in a housing compartment comprising a capsule and administering the housing compartment filed with the powder form of the therapeutically effective amount of pazopanib to the subject for a period of at least 6 months.

Abstract: The present application belongs to the technical field of medicines, and specifically relates to a pharmaceutical composition for preventing and/or treating a cancer, in particular to a pharmaceutical composition containing a CDK4/6 inhibitor compound of Formula (I) or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent or a pharmaceutically acceptable salt thereof at a fixed ratio or a fixed dose, a use of the above pharmaceutical composition in preparation of a drug for preventing and/or treating a cancer, and a kit containing the pharmaceutical composition.

Abstract: Described herein are methods for treating ALK5-mediated disease including myelodysplastic syndrome (MDS), anemia and anemia of chronic disease. Also provided are methods of inhibiting ALK5.

Abstract: Compositions and methods for the treatment of hair growth and the prevention of hair loss.

Abstract: Pharmaceutical compositions comprising Lemborexant or a pharmaceutically acceptable salt thereof and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering Lemborexant or a pharmaceutically acceptable salt thereof and an NRI are described herein. In some embodiments, the NRI is atomoxetine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions further comprise a muscarinic receptor antagonist (MRA). In some embodiments, the methods of treating Sleep Apnea further comprise administering an MRA. In some embodiments, the MRA is oxybutynin or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use of inhibitors of the P2X4 receptor or inhibitors of the P2X4 receptor signaling pathway in combination with an effective amount of a “cell death inducing chemotherapeutic drug” or “cell death inducing therapy” in the prevention and/or treatment of a solid tumor or metastases thereof in a subject, in particular in colorectal cancer (CRC).

Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.

Abstract: An application of a pyrido[1,2-a]pyrimidinone analog or a pharmaceutically acceptable salt thereof in the preparation of a drug, the drug being used to treat and/or prevent one or more among PIK3CA-mutated breast cancer, PIK3CA-mutated ovarian cancer, PIK3CA-mutated endometrial cancer, PIK3CA-mutated cervical cancer, and PIK3CA-mutated bladder cancer.